The efficiency of autologous stem cell transplantation as the first-line treatment for nodal peripheral T-cell lymphoma: results of a systematic review and meta-analysis

Zhai, Yixin; Wang, Jinhuan; Jiang, Yanan; Lv, Yangyang; Xu, Hong; Tian, Linyan; Sun, Huimeng; Zhao, Zhigang; Li, Lanfang

doi:10.1080/17474086.2022.2042247

Cited by 4 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast with the non-ASCT group, the ASCT group improved the 2-year OS rates (93.3% vs. 52.9%) for patients with AITL in the first complete remission in a previous study ( 18 ). Additionally, results of a meta-analysis showed that ASCT significantly improved OS for AITL patients, indicating ASCT could serve as the first-line consolidation treatment strategy for AITL patients ( 19 ). A similar pattern was observed in our cases, with 4 patients who underwent ASCT or pharmacologic maintenance therapy and remained in sustained remission.…”

Section: Discussionmentioning

confidence: 99%

Case report: Good response to CMOP regimen containing mitoxantrone hydrochloride liposome (PLM60) as induction chemotherapy in patients with angioimmunoblastic T-cell lymphoma

Liang,

Jiang

2024

Front. Oncol.

View full text Add to dashboard Cite

Angioimmunoblastic T-cell lymphoma (AITL) is a highly aggressive subtype of peripheral T-cell lymphoma. The current prognosis with the first-line standard of care remains unsatisfactory, necessitating the exploration of more effective treatment options. We reported 5 cases of AITL receiving CMOP (mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine, and prednisone). Cases 1 and 2 initially received CHOP as first-line induction therapy but switched to CMOP due to inadequate efficacy and cardiac adverse events. Cases 3, 4, and 5 were newly diagnosed and received CMOP. All patients achieved complete remission with acceptable cardiotoxicities and hematologic toxicities. After study treatment discontinuation, Cases 1 and 3 underwent autologous stem cell transplantation, and Cases 4 and 5 received oral maintenance agents. At the last follow-up, 4 patients remained in remission and 1 (Case 2) exhibited tumor recurrence. CMOP showed promise as a potential treatment option for AITL patients. Further research is essential to identify its efficacy and safety.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report: Good response to CMOP regimen containing mitoxantrone hydrochloride liposome (PLM60) as induction chemotherapy in patients with angioimmunoblastic T-cell lymphoma

Liang,

Jiang

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is known as an efficacious treatment which can achieve longterm remissions in patients with peripheral T-cell lymphoma [1][2]. But the prognosis of patients with peripheral T-cell lymphoma without reaching a complete remission appears to be unfavourable following ASCT [3][4]. So the impact of ASCT in the management of patients with peripheral T-cell lymphomas remains unclear .…”

Section: Introductionmentioning

confidence: 99%

Long-Term Remissions in Patients with Peripheral T-Cell Lymphoma Following High-Dose Chemotherapy, Autologous Stem Cell Transplantation (ASCT) and Subsequent Radiotherapy

Metzner,

Welzel

et al. 2023

IJCST

View full text Add to dashboard Cite

Purpose: The prognosis of patients with peripheral T-cell lymphoma and missing complete remission or relapsing before ASCT is assessed to be unfavourable. The aim of this study is to contribute data to the open question, whether additional radiotherapy improves the outcome. Patients and Methods: Forty-eight patients with peripheral T-cell-lymphoma were treated in our institution with high-dose therapy (usually BEAM protocol) and ASCT (age median 54 years, range 19-77). Twenty-five patients received ASCT in first treatment line, 13 in second line, 10 in third line (all refractory to 2nd-line salvage therapy). Seven of these 48 patients received radiotherapy (36-40 Gy, median 36) after ASCT. Results: Five-year overall survival (OS) and progression-free survival (PFS) after 1st-line ASCT and 2nd-line ASCT were 59% and 50%, respectively, and after 3rd-line ASCT significantly lower with 30% and 30%, respectively. Twenty-one patients achieved a sustained complete remission of 2.7 - 22.7 years (median 5.8). No patient relapsed after radiotherapy. Conclusion: Sustained long-term remissions can be achieved in patients with peripheral T-cell lymphoma following ASCT in first, second or third treatment line. Early irradiation after ASCT can possibly consolidate remission in localized residual or refractory disease.

show abstract

Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

Zhang,

Rose,

Khadka

et al. 2024

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

The efficiency of autologous stem cell transplantation as the first-line treatment for nodal peripheral T-cell lymphoma: results of a systematic review and meta-analysis

Cited by 4 publications

References 38 publications

Case report: Good response to CMOP regimen containing mitoxantrone hydrochloride liposome (PLM60) as induction chemotherapy in patients with angioimmunoblastic T-cell lymphoma

Case report: Good response to CMOP regimen containing mitoxantrone hydrochloride liposome (PLM60) as induction chemotherapy in patients with angioimmunoblastic T-cell lymphoma

Long-Term Remissions in Patients with Peripheral T-Cell Lymphoma Following High-Dose Chemotherapy, Autologous Stem Cell Transplantation (ASCT) and Subsequent Radiotherapy

Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

Contact Info

Product

Resources

About